---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000026"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:50:29.566254+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q1 adj EPS $2.46 (+6.5%), revenue $13.34B (+8.4%); raises FY EPS guidance to $12.09-$12.29

## Summary
- Q1 GAAP EPS $0.72 (down 6.5%), adjusted EPS $2.46 (up 6.5%); revenue $13.34B (+8.4% reported).
- Immunology growth: Skyrizi $3.43B (+70.5%), Rinvoq $1.72B (+57.2%); Humira $1.12B (-50.6%).
- Aesthetics down 11.7% to $1.10B; Botox Cosmetic -12.3%, Juvederm -22.2%.
- FY2025 adjusted diluted EPS guidance raised to $12.09-$12.29 from $11.99-$12.19.
- CEO Robert A. Michael elected chairman effective July 1, 2025, succeeding Richard A. Gonzalez.

## SEC filing metadata
- accession: 0001551152-25-000026
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/0001551152-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000026
- JSON: https://secwatch.observer/filing/0001551152-25-000026.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.